 trial miss primari endpoint
first cohort downgrad neutral
messag announc trial miss primari endpoint
cohort evalu poziotinib egfr exon non-smal cell lung cancer nsclc
overal respons rate orr significantli estim would
necessari support potenti acceler approv see significantli
lower confid drug potenti still on-going set cohort
consist downsid scenario highlight previous rolonti
pdufa date think long-act g-csf market could
challeng context biosimilar alreadi launch downgrad neutral
cohort clinic trial miss primari endpoint egfr
exon nsclc trial read orr median respons durat
month result disappoint consist downsid scenario
previous highlight preview link recal previou result poziotinib
similar egfr nsclc patient indic orr confirm
evalu patient exclud addit patient investigator-sponsor trial
md anderson caveat shift singl site trial local assess
multi-sit studi central assess base data think
abl pursu acceler approv path poziotinib nsclc chanc
potenti posit randomized-control phase trial slim view prior
analysi indic orr bar pursu acceler approv path would
low confid poziotinib potenti indic base today
news competitor agent pose addit potenti threat recal
trial evalu poziotinib addit patient popul cohort evalu
poziotinib exon nsclc egfr exon nsclc respect
schedul read sometim cohort previous guid read
link disappoint result cohort releas today reduc confid
poziotinib clinic profil competitor agent pose addit threat recal
competitor takeda tak exampl read data egfr inhibitor
link includ confirm orr takeda recent provid guidanc
 day present pivot phase data nsclc expect
regulatori approv well expect approv front-lin nsclc
manag implement earlier treatment could potenti improv durat
therapi month durat grade diarrhea vs month grade
rolonti provid potenti floor valu g-csf market like
challeng view potenti launch like late pend
approv separ announc today rolonti bla file accept
see prior note octob pdufa date recal rolonti
long-act g-csf achiev non-inferior neulasta face
biosimilar competit fulphila udenyca ziextenzo novn
remain confid rolonti approv po assum peak share
correspond peak sale within long-act g-csf given competit
neulasta multipl biosimilar updat model estim reflect
downgrad neutral buy remov pt previous
remov poziotinib model estim
page analyst certif import disclosur
valuat risk
valu use discount cash flow analysi use
wacc consist clinical-stag biotech compani cover
proof-of-concept data well termin growth rate downsid risk includ
 regulatori commerci setback potenti emerg new competitor
lower product sale expect dilut financ beyond
assum upsid risk includ higher product sale forecast
page analyst certif import disclosur
servic revenu
amort intang asset
total cost expens
interest incom net
loss extinguish debt
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
